19532-40-2

Usage

Uses

Used in Pharmaceutical Research:
1–(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid is used as a research compound for its potential anti-inflammatory properties. It is valued for its ability to inhibit the production of prostaglandins, which play a role in physiological processes such as inflammation, fever, and pain.
Used in Drug Development:
In the field of drug development, 1–(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid is used as a lead compound for the creation of new medications. Its pharmacological potential is being investigated for the treatment of various diseases and conditions, making it a compound of significant interest within the pharmaceutical industry.

Upstream product

• 829-31-2 3-(4-chlorophenyl)sydnone 
• 106-39-8 bromochlorobenzene 
• 19532-35-5 ethyl 1–(4-chlorophenyl)-1H-pyrazole-3-carboxylate 

Downstream Products

• 1613021-00-3 1-(4-chlorophenyl)-N-[(3S)-1-pyrrolo[1,2-a]pyrazin-1-ylpyrrolidin-3-yl]pyrazole-3-carboxamide trifluoroacetate 
• 1613022-37-9 1-(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid [1-(3-methylpyrrolo[1,2-a]pyrazin-1-yl)-pyrrolidin-3-yl]-amide 
• 1613022-38-0 C₂₂H₂₁ClN₆O*C₂HF₃O₂ 
• 1613020-99-7 C₂₁H₁₉ClN₆O 
• 1613020-97-5 1-(4-chlorophenyl)-N-[(3S)-1-(8-methylpyrrolo[1,2-a]pyrazin-1-yl)pyrrolidin-3-yl]pyrazole-3-carboxamide 
• 1613021-42-3 1-(4-chlorophenyl)-N-[(3S)-3-(hydroxymethyl)-1-pyrrolo[1,2-a]pyrazin-1-yl-pyrrolidin-3-yl]pyrazole-3-carboxamide 

Relevant academic research and scientific papers

Novel pyrazole derivatives via ring transformations: Anti-inflammatory and antifungal activity studies

In this paper, the synthesis of novel pyrazoles and their in vitro anti-inflammatory and in-vitro antifungal assay have been reported. These compounds were docked into the inducible nitric oxide synthase (iNOS) oxygenase dimer. The compounds 3c, 7a, 7c, 8

Discovery of novel fragments inhibiting O-acetylserine sulphhydrylase by combining scaffold hopping and ligand–based drug design

Several bacteria rely on the reductive sulphur assimilation pathway, absent in mammals, to synthesise cysteine. Reduction of virulence and decrease in antibiotic resistance have already been associated with mutations on the genes that codify cysteine biosynthetic enzymes. Therefore, inhibition of cysteine biosynthesis has emerged as a promising strategy to find new potential agents for the treatment of bacterial infection. Following our previous efforts to explore OASS inhibition and to expand and diversify our library, a scaffold hopping approach was carried out, with the aim of identifying a novel fragment for further development. This novel chemical tool, endowed with favourable pharmacological characteristics, was successfully developed, and a preliminary Structure–Activity Relationship investigation was carried out.

CXCR7 ANTAGONISTS

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.